Lilly Zyprexa IM "Approvable"; GMP Consultants Hired In Wake Of Inspections
Executive Summary
Lilly believes Zyprexa IM is on track for a late summer launch following receipt of an "approvable" letter from FDA.
You may also be interested in...
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
Lilly Symbyax Combo Clears FDA; Price, Dose Will Help Distinguish Brand
Lilly's launch plans for the bipolar depression therapy Symbyax combine a value pricing model with a unique dosing combination